SCHEMBL2217612

SCHEMBL2217612

COc1ccc2cc(I)ccc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.60
CYP1A2 P05177 1/20 0.60
HSD17B1 P14061 1/20 0.52
HSD17B2 P37059 1/20 0.52
APP P05067 5/20 0.50
KDM4E B2RXH2 1/20 0.48
GSTP1 P09211 1/20 0.48
NCF1 P14598 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45
KMT2A Q03164 1/20 0.45
NQO1 P15559 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8749237 0.96 CYP2A6 (0.61) CYP2A6CYP1A2HSD17B1HSD17B2APP
SCHEMBL29447161 0.84 CYP1A2 (0.79) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL443070 0.84 CYP1A2 (0.79) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL7452675 0.79 CYP1A2 (0.71) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL7451812 0.79 CYP1A2 (0.71) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL29367032 0.79 CYP2A6 (0.80) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL6891918 0.79 CYP1A2 (0.71) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL443528 0.79 CYP2A6 (0.80) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL2249185 0.79 CYP1A2 (0.71) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E
SCHEMBL7456084 0.79 CYP1A2 (0.71) CYP2A6CYP1A2HSD17B1HSD17B2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111704558-B Method for preparing phenyl-2- (2' -cyanophenyl) acetylene compounds by palladium catalysis 浙江农林大学暨阳学院 2023-05-30 CN disclosed
CN-111704558-A Method for preparing phenyl-2- (2' -cyanophenyl) acetylene compounds by palladium catalysis 浙江农林大学暨阳学院 2020-09-25 CN disclosed
EP-2872490-B1 ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES HOFFMANN LA ROCHE (CH) 2018-02-07 EP disclosed
US-9611224-B2 Antiproliferative benzo [B] azepin-2-ones HOFFMANN-LA ROCHE INC. (US) 2017-04-04 US disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 WO disclosed
US-20150353499-A1 ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES HOFFMAN-LA ROCHE INC. (US) 2015-12-10 US disclosed
EP-2872490-A1 ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES F. Hoffmann-La Roche AG (CH) 2015-05-20 EP disclosed
WO-2014009495-A1 ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES F. HOFFMANN-LA ROCHE AG (CH) 2014-01-16 WO disclosed
US-8455563-B2 Reactive mesogenic compounds and mixtures MERCK PATENT GMBH (DE) 2013-06-04 US disclosed
US-8455563-B2 Reactive mesogenic compounds and mixtures MERCK PATENT GMBH (DE) 2013-06-04 US disclosed
WO-2002024619-A1 AMINE COMPOUNDS BTG INTERNATIONAL LIMITED (GB) 2002-03-28 WO disclosed
EP-0668259-A1 A method for the preparation of optically active 2-aryl alkyl aldehydes and formation of 2-aryl-alkanoic acids therefrom MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) 1995-08-23 EP disclosed
US-5434302-A Method for the preparation of optically active 2-aryl alkyl aldehydes and formation of 2-aryl-alkanoic acids therefrom PARADIES H HENRICH (DE) 1995-07-18 US disclosed
EP-0221677-B1 P-AMINOPHENOLS, DERIVATIVES THEREOF AND USE FOR MANUFACTURE OF A MEDICAMENT E.R. Squibb & Sons, Inc. (US) 1992-09-09 EP disclosed
US-4910208-A Skin disorders, antiinflammatory agent E. R. SQUIBB & SONS, INC. (US) 1990-03-20 US disclosed
US-4814454-A ANTIALLERGENS, ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1989-03-21 US disclosed
US-4723033-A REACTING ALPHA METAL ACID DERIVATIVE AND ARYL HALIDE WITH OPTICALLY ACTIVE CATALYST SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) 1988-02-02 US disclosed
EP-0221677-A2 p-Aminophenols, derivatives thereof and use for manufacture of a medicament E.R. Squibb & Sons, Inc. (US) 1987-05-13 EP disclosed
EP-0110671-B1 PREPARATION OF OPTICALLY ACTIVE ALPHA-ARYLALKANOIC ACIDS AND PRECURSORS THEREOF SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1986-05-21 EP disclosed
EP-0110671-A1 Preparation of optically active alpha-arylalkanoic acids and precursors thereof SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1984-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353499-A1 ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES CCNY, RB1, TOP2B CYP2A6 3509/4885CYP1A2 2008/4885HSD17B1 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.